Cortexyme (CRTX) Stock Analysis

What Cortexyme does

Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.

Key metrics

ETFs linked to CRTX

Broad-market and Healthcare sector ETFs an investor holding Cortexyme is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CRTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cortexyme?

Cortexyme trades under the ticker CRTX on NASDAQ.

Which exchange is CRTX listed on?

CRTX is listed on NASDAQ.

What sector does Cortexyme operate in?

Cortexyme is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CRTX in a portfolio?

PortView shows CRTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.